Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 3, 2013, Pages 147-160

  Liew, Wendy K M ^a   Kang, Peter B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Duchenne muscular dystrophy; spinal muscular atrophy; therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATALUREN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; HISTONE DEACETYLASE INHIBITOR; MYOSTATIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1;

CELL THERAPY; CHILDHOOD CANCER; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; HUMAN; LIFE EXPECTANCY; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINAL MUSCULAR ATROPHY; STOP CODON;

EID: 84879315275     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612472386     Document Type: Review

References (115)

1. Aartsma-Rus A. Fokkema I. Verschuuren J. Ginjaar I. van Deutekom J. van Ommen G. et al. (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation 30: 293-299.
2. Andreassi C. Angelozzi C. Tiziano F. Vitali T. de Vincenzi E. Boninsegna A. et al. (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Human Genet 12: 59-65.
3. Angelozzi C. Borgo F. Tiziano F. Martella A. Neri G. Brahe C. (2008) Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 45: 29-31.
4. Auld D. Thorne N. Maguire W. Inglese J. (2009) Mechanism of PTC 124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A 106: 3585-3590.
5. Barton-Davis E. Cordier L. Shoturma D. Leland S. Sweeney H. (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104: 375-381.
6. Barton E. Morris L. Musaro A. Rosenthal N. Sweeney H. (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157: 137-148.
7. Berger J. Berger S. Hall T. Lieschke G. Currie P. (2010) Dystrophin-deficient zebrafish feature aspects of the Duchenne muscular dystrophy pathology. Neuromuscul Disord 20: 826-832.
8. Biggar W. Harris V. Eliasoph L. Alman B. (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16: 249-255.
9. Blau H. (2008) Cell therapies for muscular dystrophy. N Engl J Med 359: 1403-1405.
10. Bromberg M. Swoboda K. (2002) Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 25: 445-447.
11. Bulfield G. Siller W. Wight P. Moore K. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81: 1189-1192.
12. Bushby K. Finkel R. Birnkrant D. Case L. Clemens P. Cripe L. et al. (2010 a) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
13. Bushby K. Finkel R. Birnkrant D. Case L. Clemens P. Cripe L. et al. (2010 b) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177-189.
14. Chapman V. Miller D. Armstrong D. Caskey C. (1989) Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci U S A 86: 1292-1296.
15. Chen T. Chang J. Yang Y. Mai H. Liang W. Wu Y. et al. (2010) Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology 75: 2190-2197.
16. Cirak S. Arechavala-Gomeza V. Guglieri M. Feng L. Torelli S. Anthony K. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
17. Cohn R. van Erp C. Habashi J. Soleimani A. Klein E. Lisi M. et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
18. Cooper B. Winand N. Stedman H. Valentine B. Hoffman E. Kunkel L. et al. (1988) The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334: 154-156.
19. Cossu G. Molinaro M. (1987) Cell heterogeneity in the myogenic lineage. Curr Top Dev Biol 23: 185-208.
20. Crawford T. Paushkin S. Kobayashi D. Forrest S. Joyce C. Finkel R. et al. (2012) Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PloS ONE 7 (4): e33572.
21. Darras B. (2011) Non-5q spinal muscular atrophies: the alphanumeric soup thickens. Neurology 77: 312-314.
22. Darras B. Kang P. (2007) Clinical trials in spinal muscular atrophy. Curr Opin Pediat 19: 675-679.
23. Deconinck A. Rafael J. Skinner J. Brown S. Potter A. Metzinger L. et al. (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727.
24. Dickson A. Osman E. Lorson C. (2008) A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Human Gene Ther 19: 1307-1315.
25. Ebert A. Yu J. Rose F. Jr Mattis V. Lorson C. Thomson J. et al. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457: 277-280.
26. Farini A. Razini P. Erratico S. Torrente Y. Meregalli M. (2009) Cell based therapy for Duchenne muscular dystrophy. J Cell Physiol 221: 526-534.
27. Ferrari G. Cusella-de Angelis G. Coletta M. Paolucci E. Stornaiuolo A. Cossu G. et al. (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279: 1528-1530.
28. Fougerousse F. Bartoli M. Poupiot J. Arandel L. Durand M. Guerchet N. et al. (2007) Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector. Mol Ther 15: 53-61.
29. Foust K. Wang X. McGovern V. Braun L. Bevan A. Haidet A. et al. (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
30. Galvez B. Sampaolesi M. Brunelli S. Covarello D. Gavina M. Rossi B. et al. (2006) Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J Cell Biol 174: 231-243.
31. Garbes L. Riessland M. Holker I. Heller R. Hauke J. Trankle C. et al. (2009) LBH 589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Human Mol Genet 18: 3645-3658.
32. Goemans N. Tulinius M. van den Akker J. Burm B. Ekhart P. Heuvelmans N. et al. (2011) Systemic administration of PRO 051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
33. Goudenege S. Pisani D. Wdziekonski B. Di Santo J. Bagnis C. Dani C. et al. (2009) Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of Myo D. Mol Ther 17: 1064-1072.
34. Grady R. Teng H. Nichol M. Cunningham J. Wilkinson R. Sanes J. (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90: 729-738.
35. Gussoni E. Bennett R. Muskiewicz K. Meyerrose T. Nolta J. Gilgoff I. et al. (2002) Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 110: 807-814.
36. Gussoni E. Pavlath G. Lanctot A. Sharma K. Miller R. Steinman L. et al. (1992) Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356: 435-438.
37. Gussoni E. Soneoka Y. Strickland C. Buzney E. Khan M. Flint A. et al. (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401: 390-394.
38. Guyon J. Goswami J. Jun S. Thorne M. Howell M. Pusack T. et al. (2009) Genetic isolation and characterization of a splicing mutant of zebrafish dystrophin. Hum Mol Genet 18: 202-211.
39. Hirawat S. Welch E. Elfring G. Northcutt V. Paushkin S. Hwang S. et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47: 430-444.
40. Hoffman E. Brown R. Jr Kunkel L. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
41. Howard M. Anderson C. Fass U. Khatri S. Gesteland R. Atkins J. et al. (2004) Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 55: 422-426.
42. Hua Y. Sahashi K. Hung G. Rigo F. Passini M. Bennett C. et al. (2010) Antisense correction of SMN 2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24: 1634-1644.
43. Hua Y. Sahashi K. Rigo F. Hung G. Horev G. Bennett C. et al. (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478: 123-126.
44. Huard J. Bouchard J. Roy R. Malouin F. Dansereau G. Labrecque C. et al. (1992) Human myoblast transplantation: preliminary results of 4 cases. Muscle Nerve 15: 550-560.
45. Jackson K. Mi T. Goodell M. (1999) Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci U S A 96: 14482-14486.
46. Kang P. Krishnamoorthy K. Jones R. Shapiro F. Darras B. (2006) Atypical presentations of spinal muscular atrophy type III (Kugelberg–Welander disease). Neuromuscul Disord 16: 492-494.
47. Kang P. Lidov H. White A. Mitchell M. Balasubramanian A. Estrella E. et al. (2010) Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. Muscle Nerve 41: 746-750.
48. Karpati G. Ajdukovic D. Arnold D. Gledhill R. Guttmann R. Holland P. et al. (1993) Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 34: 8-17.
49. Kaufmann P. McDermott M. Darras B. Finkel R. Kang P. Oskoui M. et al. (2011) Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 68: 779-786.
50. Kaufmann P. McDermott M. Darras B. Finkel R. Sproule D. Kang P. et al. (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79: 1889-1897.
51. Kinali M. Arechavala-Gomeza V. Feng L. Cirak S. Hunt D. Adkin C. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
52. Kinali M. Mercuri E. Main M. de Biasia F. Karatza A. Higgins R. et al. (2002) Pilot trial of albuterol in spinal muscular atrophy. Neurology 59: 609-610.
53. Koenig M. Hoffman E. Bertelson C. Monaco A. Feener C. Kunkel L. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517.
54. Krosschell K. Maczulski J. Crawford T. Scott C. Swoboda K. (2006) A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 16: 417-426.
55. Lee J. Qu-Petersen Z. Cao B. Kimura S. Jankowski R. Cummins J. et al. (2000) Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol 150: 1085-1100.
56. Lefebvre S. Burglen L. Reboullet S. Clermont O. Burlet P. Viollet L. et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165.
57. Lefebvre S. Burlet P. Liu Q. Bertrandy S. Clermont O. Munnich A. et al. (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265-269.
58. Lewelt A. Krosschell K. Scott C. Sakonju A. Kissel J. Crawford T. et al. (2010) Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 42: 703-708.
59. Li Y. Foster W. Deasy B. Chan Y. Prisk V. Tang Y. et al. (2004) Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164: 1007-1019.
60. Luth E. Jun S. Wessen M. Liadaki K. Gussoni E. Kunkel L. (2008) Bone marrow side population cells are enriched for progenitors capable of myogenic differentiation. J Cell Sci 121: 1426-1434.
61. Mailman M. Heinz J. Papp A. Snyder P. Sedra M. Wirth B. et al. (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Gen Med 4: 20-26.
62. Main M. Kairon H. Mercuri E. Muntoni F. (2003) The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediat Neurol 7: 155-159.
63. Malik V. Rodino-Klapac L. Viollet L. Wall C. King W. Al-Dahhak R. et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67: 771-780.
64. Markowitz J. Singh P. Darras B. (2012) Spinal muscular atrophy: a clinical and research update. Pediat Neurol 46: 1-12.
65. Marshall E. (1999) Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.
66. Mazzone E. Martinelli D. Berardinelli A. Messina S. D'Amico A. Vasco G. et al. (2010) North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20: 712-716.
67. McComas A. (1991) Invited review: motor unit estimation: methods, results, and present status. Muscle Nerve 14: 585-597.
68. McDonald C. Henricson E. Han J. Abresch R. Nicorici A. Atkinson L. et al. (2010) The 6-minute walk test in Duchenne / Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42: 966-974.
69. Mendell J. Campbell K. Rodino-Klapac L. Sahenk Z. Shilling C. Lewis S. et al. (2010 a) Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437.
70. Mendell J. Kissel J. Amato A. King W. Signore L. Prior T. et al. (1995) Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 333: 832-838.
71. Mendell J. Rodino-Klapac L. Rosales-Quintero X. Kota J. Coley B. Galloway G. et al. (2009) Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 66: 290-297.
72. Mendell J. Rodino-Klapac L. Rosales X. Coley B. Galloway G. Lewis S. et al. (2010 b) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629-638.
73. Meng J. Adkin C. Xu S. Muntoni F. Morgan J. (2011 a) Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. PloS ONE 6 (3): e17454.
74. Meng J. Muntoni F. Morgan J. (2011 b) Stem cells to treat muscular dystrophies - where are we? Neuromuscul Disord 21: 4-12.
75. Mercuri E. Bertini E. Messina S. Solari A. D'Amico A. Angelozzi C. et al. (2007) Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 68: 51-55.
76. Miller R. Sharma K. Pavlath G. Gussoni E. Mynhier M. Lanctot A. et al. (1997) Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 20: 469-478.
77. Monaco A. Neve R. Colletti-Feener C. Bertelson C. Kurnit D. Kunkel L. (1986) Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323: 646-650.
78. Montes J. Gordon A. Pandya S. de Vivo D. Kaufmann P. (2009) Clinical outcome measures in spinal muscular atrophy. J Child Neurol 24: 968-978.
79. Montes J. McDermott M. Martens W. Dunaway S. Glanzman A. Riley S. et al. (2010) Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74: 833-838.
80. Muntoni F. Wood M. (2011) Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10: 621-637.
81. Nelson L. Owens H. Hynan L. Iannaccone S. (2006) The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord 16: 374-380.
82. O'Hagen J. Glanzman A. McDermott M. Ryan P. Flickinger J. Quigley J. et al. (2007) An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 17: 693-697.
83. Odom G. Gregorevic P. Allen J. Finn E. Chamberlain J. (2008) Microutrophin delivery through rAAV 6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 16: 1539-1545.
84. Pacak C. Walter G. Gaidosh G. Bryant N. Lewis M. Germain S. et al. (2007) Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther 15: 1775-1781.
85. Pane M. Staccioli S. Messina S. D'Amico A. Pelliccioni M. Mazzone E. et al. (2008) Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 18: 536-540.
86. Passini M. Bu J. Richards A. Kinnecom C. Sardi S. Stanek L. et al. (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3 (72): 72ra18.
87. Passini M. Bu J. Roskelley E. Richards A. Sardi S. O'Riordan C. et al. (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120: 1253-1264.
88. Pearn J. (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15: 409-413.
89. Pearn J. (1980) Classification of spinal muscular atrophies. Lancet 1: 919-922.
90. Porensky P. Mitrpant C. McGovern V. Bevan A. Foust K. Kaspar B. et al. (2012) A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 21: 1625-1638.
91. Ryder-Cook A. Sicinski P. Thomas K. Davies K. Worton R. Barnard E. et al. (1988) Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 7: 3017-3021.
92. Sacco A. Doyonnas R. Kraft P. Vitorovic S. Blau H. (2008) Self-renewal and expansion of single transplanted muscle stem cells. Nature 456: 502-506.
93. Sacco A. Mourkioti F. Tran R. Choi J. Llewellyn M. Kraft P. et al. (2010) Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx / mTR mice. Cell 143: 1059-1071.
94. Schuelke M. Wagner K. Stolz L. Hubner C. Riebel T. Komen W. et al. (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350: 2682-2688.
95. Scott J. Li S. Harper S. Welikson R. Bourque D. DelloRusso C. et al. (2002) Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord 12(Suppl. 1): S23-S29.
96. Sejerson T. Bushby K. (2009) Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations. Adv Exp Med Biol 652: 13-21.
97. Sharp N. Kornegay J. van Camp S. Herbstreith M. Secore S. Kettle S. et al. (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13: 115-121.
98. Sicinski P. Geng Y. Ryder-Cook A. Barnard E. Darlison M. Barnard P. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580.
99. Stillwell E. Vitale J. Zhao Q. Beck A. Schneider J. Khadim F. et al. (2009) Blastocyst injection of wild type embryonic stem cells induces global corrections in mdx mice. PloS ONE 4 (3): e4759.
100. Sumner C. Huynh T. Markowitz J. Perhac J. Hill B. Coovert D. et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54: 647-654.
101. Sumner C. Kolb S. Harmison G. Jeffries N. Schadt K. Finkel R. et al. (2006) SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 66: 1067-1073.
102. Swoboda K. Prior T. Scott C. McNaught T. Wride M. Reyna S. et al. (2005) Natural history of denervation in SMA: relation to age, SMN 2 copy number, and function. Ann Neurol 57: 704-712.
103. Swoboda K. Scott C. Reyna S. Prior T. LaSalle B. Sorenson S. et al. (2009) Phase II open label study of valproic acid in spinal muscular atrophy. PloS ONE 4 (5): e5268.
104. Tinsley J. Deconinck N. Fisher R. Kahn D. Phelps S. Gillis J. et al. (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4: 1441-1444.
105. Tiziano F. Lomastro R. Pinto A. Messina S. D'Amico A. Fiori S. et al. (2010) Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 47: 856-858.
106. Tremblay J. Bouchard J. Malouin F. Theau D. Cottrell F. Collin H. et al. (1993) Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. Neuromuscul Disord 3: 583-592.
107. van Deutekom J. Janson A. Ginjaar I. Frankhuizen W. Aartsma-Rus A. Bremmer-Bout M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
108. van Ommen G. van Deutekom J. Aartsma-Rus A. (2008) The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Therapeut 10: 140-149.
109. Wagner K. (2008) Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 5: 583-591.
110. Wagner K. Fleckenstein J. Amato A. Barohn R. Bushby K. Escolar D. et al. (2008) A phase I / II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63: 561-571.
111. Wagner K. McPherron A. Winik N. Lee S. (2002) Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52: 832-836.
112. Wang C. Finkel R. Bertini E. Schroth M. Simonds A. Wong B. et al. (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22: 1027-1049.
113. Welch E. Barton E. Zhuo J. Tomizawa Y. Friesen W. Trifillis P. et al. (2007) PTC 124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91.
114. Williams J. Schray R. Patterson C. Ayitey S. Tallent M. Lutz G. (2009) Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 29: 7633-7638.
115. Wu J. Darras B. Rutkove S. (2010) Assessing spinal muscular atrophy with quantitative ultrasound. Neurology 75: 526-531.